All updated as on -
By 2030, the market for beta-thalassemia is anticipated to reach USD 823.7 million, growing at a 9% CAGR from 2023 to 2030.
The market is anticipated to expand in the coming years as the number of persons who have beta-thalassemia increases globally. According to a report released in November 2018 by the international biopharmaceutical corporation Bristol-Myers Squibb corporation, between 80 and 90 million people worldwide, or around 1.5% of the total population, carry the beta-thalassemia gene. Although beta-thalassemia is not highly prevalent in the US, 1.25 million people, or 0.4% of the population, are believed to be carriers. Additionally, according to the same source, 1,000 of the 2,000 thalassemia patients in the United States had -thalassemia major.
A specific form of blood condition is beta-thalassemia. a genetic condition in which the body produces significantly less haemoglobin than is typical. The protein that contains iron and is known by the name "haemoglobin" is found in red blood cells. It is responsible for delivering oxygen to all of the body's cells. Because of the low haemoglobin level, numerous body parts will have even lower oxygen levels. Modifications to the HBB gene are the cause of beta-thalassemia. The HBB gene is in charge of transmitting the information required to produce the protein beta-globin. Numerous signs of this condition include anaemia, breathing difficulties, weariness, a rapid heartbeat, irritability, jaundice, and delayed development, to name a few. Beta-thalassemia is also referred to as Mediterranean anaemia. Thalassemia cases are on the rise, which will significantly contribute to the market's expansion. Other significant factors, such as the rising cost of medical care, also have an impact on the beta-thalassemia market's rate of expansion.
The market for beta-thalassemia will expand as a result of advancements in medical technology, increased awareness-raising initiatives by both public and private organisations, and more funding from the government. Other factors, such as the increasing need for potent medications and the rise in the number of elderly people, are probably going to aid in the market's growth rate for beta-thalassemia. The beta-thalassemia sector will expand as a result of factors such changing lifestyles and an increase in consumers spending money on unnecessary items. A rise in the number of people who undergo genetic testing early and the number of people who seek genetic counselling will both support the expansion of the beta-thalassemia business.
Report Coverage
Global Beta-Thalassemia research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Beta-Thalassemia report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Beta-Thalassemia competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Beta-Thalassemia market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Beta-Thalassemia market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Beta-Thalassemia market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Celgene Corp., BlueBird Bio, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Beta-Thalassemia market based on the below-mentioned segments:
Global Beta-Thalassemia Market, By Treatment
Global Beta-Thalassemia market, By Disease Indication
Global Beta-Thalassemia market, Regional Analysis
The market is anticipated to expand in the coming years as the number of persons who have beta-thalassemia increases globally. According to a report released in November 2018 by the international biopharmaceutical corporation Bristol-Myers Squibb corporation, between 80 and 90 million people worldwide, or around 1.5% of the total population, carry the beta-thalassemia gene. Although beta-thalassemia is not highly prevalent in the US, 1.25 million people, or 0.4% of the population, are believed to be carriers. Additionally, according to the same source, 1,000 of the 2,000 thalassemia patients in the United States had -thalassemia major.
A specific form of blood condition is beta-thalassemia. a genetic condition in which the body produces significantly less haemoglobin than is typical. The protein that contains iron and is known by the name "haemoglobin" is found in red blood cells. It is responsible for delivering oxygen to all of the body's cells. Because of the low haemoglobin level, numerous body parts will have even lower oxygen levels. Modifications to the HBB gene are the cause of beta-thalassemia. The HBB gene is in charge of transmitting the information required to produce the protein beta-globin. Numerous signs of this condition include anaemia, breathing difficulties, weariness, a rapid heartbeat, irritability, jaundice, and delayed development, to name a few. Beta-thalassemia is also referred to as Mediterranean anaemia. Thalassemia cases are on the rise, which will significantly contribute to the market's expansion. Other significant factors, such as the rising cost of medical care, also have an impact on the beta-thalassemia market's rate of expansion.
The market for beta-thalassemia will expand as a result of advancements in medical technology, increased awareness-raising initiatives by both public and private organisations, and more funding from the government. Other factors, such as the increasing need for potent medications and the rise in the number of elderly people, are probably going to aid in the market's growth rate for beta-thalassemia. The beta-thalassemia sector will expand as a result of factors such changing lifestyles and an increase in consumers spending money on unnecessary items. A rise in the number of people who undergo genetic testing early and the number of people who seek genetic counselling will both support the expansion of the beta-thalassemia business.
Report Coverage
Global Beta-Thalassemia research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Beta-Thalassemia report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Beta-Thalassemia competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Beta-Thalassemia market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Celgene Corp., BlueBird Bio, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Beta-Thalassemia Market from 2021 to 2030.
- Market Forecast for Beta-Thalassemia Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Beta-Thalassemia competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Beta-Thalassemia
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Beta-Thalassemia market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Beta-Thalassemia market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Celgene Corp., BlueBird Bio, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics
Primary Target Market
- Market Players of Beta-Thalassemia
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Beta-Thalassemia market based on the below-mentioned segments:
Global Beta-Thalassemia Market, By Treatment
- Iron Chelating Drugs
- Erythyroid maturation agents
- Stem Cell therapy
- Others
Global Beta-Thalassemia market, By Disease Indication
- Beta Thalassemia Minor
- Beta Thalassemia Intermediate
- Beta Thalassemia Major
Global Beta-Thalassemia market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive beta thalassemia market market research and competitor analysis for your business to help you develop more profound insights into the beta thalassemia market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the beta thalassemia market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.